These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7607905)

  • 41. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
    J Cell Biochem; 1994 Sep; 56(1):52-61. PubMed ID: 7806592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Isolated limb perfusion for melanoma.
    Kroon BB; Noorda EM; Vrouenraets BC; van Slooten GW; Nieweg OE
    Surg Oncol Clin N Am; 2008 Oct; 17(4):785-94, viii-ix. PubMed ID: 18722918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha.
    Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2006 May; 32(4):371-80. PubMed ID: 16520016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Locoregional use of TNF (tumor necrosis factor) in the treatment of malignant melanoma].
    Lejeune F
    Pathol Biol (Paris); 1990 Oct; 38(8):883-4. PubMed ID: 1703292
    [No Abstract]   [Full Text] [Related]  

  • 45. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
    Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
    Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
    Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic or regional chemotherapy: does it matter and should surgeons be involved?
    Stephens FO
    J R Coll Surg Edinb; 1998 Apr; 43(2):80-1. PubMed ID: 9621525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regional hyperthermic perfusion for malignant melanoma.
    Hafström LO; Ehrson H; Hugander A; Jönsson PE; Westling H
    Prog Clin Biol Res; 1982; 107():793-8. PubMed ID: 7167529
    [No Abstract]   [Full Text] [Related]  

  • 51. The application of hyperthermia in regional chemotherapy.
    Di Filippo F; Anzà M; Rossi CR; Cavaliere F; Botti C; Lise M; Garinei R; Giannarelli D; Vasselli S; Zupi G; Cavaliere R
    Semin Surg Oncol; 1998; 14(3):215-23. PubMed ID: 9548604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is there a role for isolated limb perfusion with tumor necrosis factor in patients with melanoma?
    De Wilt JH; Thompson JF
    Ann Surg Oncol; 2004 Feb; 11(2):119-21. PubMed ID: 14761911
    [No Abstract]   [Full Text] [Related]  

  • 53. [Combined treatment of malignant tumors of the extremities. Regional perfusion chemotherapy].
    Kolessov VI; Levin AO
    Minerva Med; 1970 Sep; 61(71):3673-5. PubMed ID: 4989391
    [No Abstract]   [Full Text] [Related]  

  • 54. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone.
    Edwards MJ; Soong SJ; Boddie AW; Balch CM; McBride CM
    Arch Surg; 1990 Mar; 125(3):317-21. PubMed ID: 2306179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion.
    Pigozzo J; De Rossi C; Rossi CR; Nitti D; Sileni VC
    Melanoma Res; 2009 Jun; 19(3):193-4. PubMed ID: 19436179
    [No Abstract]   [Full Text] [Related]  

  • 56. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer.
    Lejeune FJ
    Eur J Cancer; 1995 Jun; 31A(6):1009-16. PubMed ID: 7646901
    [No Abstract]   [Full Text] [Related]  

  • 57. Hyperthermic perfusion in malignant melanoma: 5-year results.
    Tonak J; Hohenberger W; Weidner F; Göhl H
    Recent Results Cancer Res; 1983; 86():229-38. PubMed ID: 6648004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hyperthermic isolation limb perfusion for malignant melanoma: a review.
    Coit DG
    Cancer Invest; 1992; 10(4):277-84. PubMed ID: 1628227
    [No Abstract]   [Full Text] [Related]  

  • 59. Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs.
    Barker WC; Andrich MP; Alexander HR; Fraker DL
    Eur J Nucl Med; 1995 Nov; 22(11):1242-8. PubMed ID: 8575471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities.
    Jönsson PE; Hafström L; Hugander A
    Recent Results Cancer Res; 1983; 86():277-82. PubMed ID: 6648009
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.